BioMark’s Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial
BioMark’s Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial Extensive Validation of BioMark’s Comprehensive Metabolic Panel in German 10,000-Participant HANSE Study, within the context of an international consortium supported under the EUREKA Network. Vancouver, British Columbia – (October 7, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a […]
Form 7 Monthly Progress Report September 2025
Form 7 Monthly Progress Report September 2025 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 105,090,213 October 5, 2025 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BioMark Secures Key Patents in Asia’s Largest Markets for Early Lung Cancer Liquid Biopsy
BioMark Secures Key Patents in Asia’s Largest Markets for Early Lung Cancer Liquid Biopsy Pioneering liquid biopsy platform for early lung cancer detection strengthens IP and accelerates commercial strategy in China and Japan diagnostic markets. Vancouver, British Columbia – (September 29, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading […]
Form 7 Monthly Progress Report August 2025
Form 7 Monthly Progress Report September 2025 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 105,090,213 September 4, 2025 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership Proof-of-Concept Trial Opens Door to 90+ Million Population Across North Africa and Francophone Markets Vancouver, British Columbia – (August 12, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, announced […]
Form 7 Monthly Progress Report July 2025
Form 7 Monthly Progress Report July 2025 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 105,090,213 August 4, 2025 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Press Release – BioMark Diagnostics Announces Expansion of its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships
Press Release – BioMark Diagnostics Announces Expansion of its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships Expansion of BioMark brings advanced equipment and doubles capacity, accelerating commercialization of lung cancer assay Vancouver, British Columbia – (August 5, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a […]
Press Release – BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 – 2026
BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 – 2026 VANCOUVER, BC – (July 30, 2025) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, today announced a summary of its fiscal year […]
Form 7 Monthly Progress Report June 2025
Form 7 Monthly Progress Report June 2025 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 105,090,213 July 3, 2025 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Press Release – BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology
Novel Graph Neural Network (N-GNN) Model Achieves Superior Accuracy in Early Lung Cancer Detection, Paving the Way for Enhanced Diagnostic Capabilities. Vancouver, British Columbia – (May 20, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leader in developing liquid biopsy tests for early cancer detection, today announced the publication of […]